Discount agreement for Follitropin alfa biologics
Titre original de l'avis
Germany – Pharmaceutical products – Open House Biologika Rabattverträge 2026-25 - Follitropin alfa
Score d'opportunité
Pourquoi ce score ?
Opportunité
46 / 100
Complexité
58 / 100
Facteurs de risque
The notice says offers/contracts cannot be submitted via the portal; they must be sent by email with qualified electron...
Participation is limited to pharmaceutical entrepreneurs for the relevant medicinal products and requires the stated au...
Analyse approfondie du portefeuille
Utilise:
- Description
- Industries & Services
- Capabilities
- Market & Experience
- Certifications
Aperçu
Moderate opportunityFaits clés
- Supplies contract
- 3 lots
- Duration until Jul 2028
- Open House discount agreements for pharmaceutical products under § 130a(8) SGB V for the active substance Follitropin alfa.
- Three lots are formed for specific branded medicines: GONAL-f, Bemfola, and Ovaleap.
Afficher le résumé complet
Open House procedure by Techniker Krankenkasse for supply-side pharmaceutical discount agreements under § 130a(8) SGB V for the active substance Follitropin alfa. Three lots are listed for specific branded medicines (GONAL-f, Bemfola, Ovaleap). The procedure is non-exclusive, with no individual negotiations, and contracts may be concluded with all eligible pharmaceutical companies that meet the stated self-declarations and sign the contract in text form/electronic form as required. Submission is not via the portal; contracts must be sent by email with qualified electronic signature or by post. Procurement documents are available on the portal, but only extracted XML notice text was provided here, not the full document set.
Risques
The notice says offers/contracts cannot be submitted via the portal; they must be sent by email with qualified electron...
Participation is limited to pharmaceutical entrepreneurs for the relevant medicinal products and requires the stated au...
L'analyse peut être incomplète
Seule une partie des documents de consultation a été analysée. Des exigences, certificats ou documents de soumission supplémentaires peuvent exister dans les documents restants.
Exigences clés
Technical
- Tenderer must be a pharmaceutical entrepreneur within the meaning of § 4(18) AMG for the offered medicinal product(s).
- Tenderer must have its registered seat in the AMG territory, another EU Member State, or another EEA state.
- Tenderer must hold a valid marketing authorisation for the relevant medicinal product(s) or otherwise be entitled to place them on the market in its own name.
Acheteur
Localisation
Hamburg, DEU
Site web
Identifiant
992-80116-93
Activité
Health
Lots (3)
LOT-0001
Follitropin alfa (GONAL-f)
Supply lot for Follitropin alfa covering the branded medicinal product GONAL-f. The lot is part of an Open House discount agreement scheme; no exclusivity and no individual negotiations apply. Performance is nationwide in Germany.
Localisation
Durée
Catégorie
Date limite
Détails des critères
Die TK verfolgt das Ziel, mit allen geeigneten pharmazeutischen Unternehmern Rabattverträge nach § 130a Abs. 8 SGB V zu dem Wirkstoff Follitropin alfa zu schließen.
Note sur la valeur
Afficher les données TED originales
Titre original du lot
Follitropin alfa (Fertigarzneimittel GONAL-f (R))
Description TED originale
Die TK verfolgt das Ziel, mit allen geeigneten pharmazeutischen Unternehmern Rabattverträge nach § 130a Abs. 8 SGB V zu dem Wirkstoff Follitropin alfa zu schließen.
LOT-0002
Follitropin alfa (Bemfola)
Supply lot for Follitropin alfa covering the branded medicinal product Bemfola. The lot is part of an Open House discount agreement scheme; no exclusivity and no individual negotiations apply. Performance is nationwide in Germany.
Localisation
Durée
Catégorie
Date limite
Détails des critères
Die TK verfolgt das Ziel, mit allen geeigneten pharmazeutischen Unternehmern Rabattverträge nach § 130a Abs. 8 SGB V zu dem Wirkstoff Follitropin alfa zu schließen.
Note sur la valeur
Afficher les données TED originales
Titre original du lot
Follitropin alfa (Fertigarzneimittel Bemfola (R))
Description TED originale
Die TK verfolgt das Ziel, mit allen geeigneten pharmazeutischen Unternehmern Rabattverträge nach § 130a Abs. 8 SGB V zu dem Wirkstoff Follitropin alfa zu schließen.
LOT-0003
Follitropin alfa (Ovaleap)
Supply lot for Follitropin alfa covering the branded medicinal product Ovaleap. The lot is part of an Open House discount agreement scheme; no exclusivity and no individual negotiations apply. Performance is nationwide in Germany.
Localisation
Durée
Catégorie
Date limite
Détails des critères
Die TK verfolgt das Ziel, mit allen geeigneten pharmazeutischen Unternehmern Rabattverträge nach § 130a Abs. 8 SGB V zu dem Wirkstoff Follitropin alfa zu schließen.
Note sur la valeur
Afficher les données TED originales
Titre original du lot
Follitropin alfa (Fertigarzneimittel Ovaleap(R))
Description TED originale
Die TK verfolgt das Ziel, mit allen geeigneten pharmazeutischen Unternehmern Rabattverträge nach § 130a Abs. 8 SGB V zu dem Wirkstoff Follitropin alfa zu schließen.
Détails de la procédure
- Date de publication
- 07 Jun 2026
- Langues
- German
Métadonnées de référence
- Base juridique
- 32014L0024
Identifiants de référence
- ID de l'appel d'offres
- 388432-2026
Documents (1)
Appels d'offres similaires
Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells über Arzneimittel mit dem Handelsnamen Orylmyte(R) (ATC-Code nach WHO: V01AA03)
Bulgaria – Pharmaceutical products – Динамична система за покупки за доставка на лекарствени продукти за Медицински институт на МВР
Belgium – Pharmaceutical products – Antimycotica
Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells über Arzneimittel mit dem Handelsnamen Oralair(R) (ATC-Code nach WHO: V01AA02)
Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells zum Wirkstoff Ipratropiumbromid (ATC-Code nach WHO: R03BB01)
Denmark – Pharmaceutical products – Amgros 2027 1.1170.a
Score d'opportunité
Pourquoi ce score ?
Opportunité
46 / 100
Complexité
58 / 100
Facteurs de risque
The notice says offers/contracts cannot be submitted via the portal; they must be sent by email with qualified electron...
Participation is limited to pharmaceutical entrepreneurs for the relevant medicinal products and requires the stated au...
Analyse approfondie du portefeuille
Utilise:
- Description
- Industries & Services
- Capabilities
- Market & Experience
- Certifications